NYSE: TAK
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes specialty pharmaceuticals and other health products. The company operates across multiple therapeutic areas and reports financial results under IFRS. Takeda generates a significant portion of its revenue from markets outside Japan, with substantial exposure to USD, EUR, CNY, BRL, and RUB currencies. The company focuses on both organic growth through new product launches and pipeline development, as well as strategic acquisitions. Takeda utilizes a transformation program to drive cost savings and operational efficiency, and manages a substantial debt portfolio following its acquisition of Shire. The company maintains hybrid subordinated bond instruments and actively manages its leverage ratio, targeting deleveraging through adjusted free cash flow generation. Takeda's R&D efforts span late-stage pipeline programs, and its product portfolio is subject to loss-of-exclusivity dynamics, including the conclusion of VYVANSE amortization. The company also maintains strategic partnerships including a global partnership agreement with Innovent Biologics and arrangements with Protagonist Therapeutics. Updated
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
Friday's top analyst upgrades and downgrades included Adobe, Citigroup, FedEx, Foot Locker, Hewlett Packard Enterprise, Intel, Medical Properties Trust, Nike, Qualcomm, Skyworks Solutions, Takeda Pharmaceutical and Under Armour.
Tuesday's additional top analyst upgrades and downgrades included Apollo Global Management, Cinemark, ConocoPhillips, EOG Resources, Fastly, Southwestern Energy, Sunrun and Takeda Pharmaceutical.
One of Cathie Wood's Ark Invest funds sold nearly 850,000 shares of Takeda Pharmaceutical on December 7.
One of Cathie Wood's Ark Invest funds sold over 690,000 shares of Takeda Pharmaceutical on November 16.
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost structures, and they…
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal…
One of Cathie Wood's Ark Invest funds sold over 350,000 shares of Takeda Pharmaceutical on June 16.
One of Cathie Wood's Ark Invest funds sold over 225,000 shares of Takeda Pharma on June 15.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes specialty pharmaceuticals and other health products. The company operates across multiple therapeutic areas and reports financial results under IFRS.
24/7 Wall St.'s 12-month price target for TAK is $24.06, rated Buy. The Wall Street consensus target is $21.99. TAK price prediction →
